Company Profile
DBV Technologies Stock Price, News & Analysis
- Ticker:
- DBVT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France
Stock performance
13.74 USD (-3.51%)
Close
Last updated: August 6, 2026
1.08B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, DBVT closed down 3.51% at $13.74. No new same-company headline was identified in the current news window.
Company overview
Business overview
DBV Technologies is a food-allergy company focused on epicutaneous immunotherapy and allergic disease. Its platform aims to use skin-based delivery to modulate immune response.
Geographic Base and Sector Classification
Headquartered in France and listed on NASDAQ as an ADR, DBV has a global allergy-biotech profile.
Business Model Characteristics
The business depends on clinical data, regulatory progress, and the potential to turn immunotherapy for allergies into a commercial story.
Position Within the Biotechnology Landscape
DBV is a niche allergy biotech whose stock is highly sensitive to regulatory and clinical updates.
Future catalysts
DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive. The next regulatory update matters because the company has spent years trying to bring the patch platform across the finish line.
Recent news
- 01
DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
Source: DBV Technologies
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of DBV Technologies (DBVT)?
DBV Technologies (DBVT) most recently closed at 13.74 USD, a -3.51% move versus the previous session.
What is the market cap of DBV Technologies (DBVT)?
DBV Technologies currently has a market capitalization of 1.08B USD on BioPharmSignal.
What does DBV Technologies do?
DBV Technologies is a food-allergy company focused on epicutaneous immunotherapy and allergic disease. Its platform aims to use skin-based delivery to modulate immune response.
On which exchange is DBVT stock listed?
DBV Technologies (DBVT) is associated with NASDAQ, France, Biopharma.
What is Technologies?
DBV Technologies is a food-allergy company focused on epicutaneous immunotherapy and allergic disease.
Which conditions is DBV Technologies targeting with Technologies?
DBV Technologies is a food-allergy company focused on epicutaneous immunotherapy and allergic disease. Its platform aims to use skin-based delivery to modulate immune response. DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive. The next regulatory update matters because the company has spent years...
How does DBV Technologies describe recent progress with Technologies?
DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive. The next regulatory update matters because the company has spent years trying to bring the patch platform across the finish line.
What is Viaskin?
DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive.